|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Carvedilol#Drug Interactions]] |
| {{Carvedilol}}
| |
| {{CMG}}; {{AE}} {{AZ}}
| |
| | |
| ===CYP2D6 Inhibitors and Poor Metabolizers===
| |
| | |
| Interactions of carvedilol with potent inhibitors of CYP2D6 isoenzyme (such as [[quinidine]], [[fluoxetine]], [[paroxetine]], and [[propafenone]]) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol [see [[Carvedilol clinical pharmacology|Clinical Pharmacology ]]]. Retrospective analysis of side effects in clinical trials showed that poor 2D6 metabolizers had a higher rate of dizziness during up-titration, presumably resulting from vasodilating effects of the higher concentrations of the α-blocking R(+) enantiomer.
| |
| | |
| ===Hypotensive Agents===
| |
| | |
| Patients taking both agents with β-blocking properties and a drug that can deplete[[ catecholamines ]](e.g., [[reserpine]] and [[monoamine oxidase]] inhibitors) should be observed closely for signs of[[ hypotension]] and/or severe[[ bradycardia]].
| |
| | |
| Concomitant administration of [[clonidine]] with agents with β-blocking properties may potentiate blood-pressure- and heart-rate-lowering effects. When concomitant treatment with agents with β-blocking properties and clonidine is to be terminated, the β-blocking agent should be discontinued first. Clonidine therapy can then be discontinued several days later by gradually decreasing the dosage.
| |
| | |
| ===Cyclosporine===
| |
| | |
| Modest increases in mean trough[[ cyclosporine]] concentrations were observed following initiation of carvedilol treatment in 21 renal transplant subjects suffering from chronic vascular rejection. In about 30% of subjects, the dose of cyclosporine had to be reduced in order to maintain cyclosporine concentrations within the therapeutic range, while in the remainder no adjustment was needed. On the average for the group, the dose of cyclosporine was reduced about 20% in these subjects. Due to wide interindividual variability in the dose adjustment required, it is recommended that cyclosporine concentrations be monitored closely after initiation of carvedilol therapy and that the dose of cyclosporine be adjusted as appropriate.
| |
| | |
| ===Digitalis Glycosides===
| |
| | |
| Both [[digitalis ]]glycosides and β-blockers slow atrioventricular conduction and decrease heart rate. Concomitant use can increase the risk of bradycardia. [[Digoxin]]concentrations are increased by about 15% when digoxin and carvedilol are administered concomitantly. Therefore, increased monitoring of digoxin is recommended when initiating, adjusting, or discontinuing COREG [see [[Carvedilol clinical pharmacology|Clinical Pharmacology ]]].
| |
| | |
| ===Inducers/Inhibitors of Hepatic Metabolism===
| |
| | |
| Rifampin reduced plasma concentrations of carvedilol by about 70% [see Clinical Pharmacology (12.5)]. Cimetidine increased AUC by about 30% but caused no change in Cmax[see [[Carvedilol clinical pharmacology|Clinical Pharmacology ]]].
| |
| | |
| ===Amiodarone===
| |
| | |
| [[Amiodarone]], and its metabolite desethyl [[amiodarone]], inhibitors of CYP2C9 and P-glycoprotein, increased concentrations of the S(-)-enantiomer of carvedilol by at least 2-fold [see [[Carvedilol clinical pharmacology|Clinical Pharmacology ]]]. The concomitant administration of amiodarone or other CYP2C9 inhibitors such as [[fluconazole]] with COREG may enhance the β-blocking properties of carvedilol resulting in further slowing of the heart rate or cardiac conduction. Patients should be observed for signs of [[bradycardia]] or heart block, particularly when one agent is added to pre-existing treatment with the other.
| |
| | |
| ===Calcium Channel Blockers===
| |
| | |
| Conduction disturbance (rarely with hemodynamic compromise) has been observed when COREG is co-administered with [[diltiazem]]. As with other agents with β-blocking properties, if COREG is to be administered with calcium channel blockers of the verapamil or diltiazem type, it is recommended that ECG and blood pressure be monitored.
| |
| | |
| ===Insulin or Oral Hypoglycemics===
| |
| | |
| Agents with β-blocking properties may enhance the blood-sugar-reducing effect of [[insulin]] and oral hypoglycemics. Therefore, in patients taking insulin or oral hypoglycemics, regular monitoring of blood glucose is recommended [see [[Carvedilol warnings and precautions|Warnings and Precautions ]]].
| |
| | |
| ===Anesthesia===
| |
| | |
| If treatment with COREG is to be continued perioperatively, particular care should be taken when anesthetic agents which depress myocardial function, such as ether, cyclopropane, and trichloroethylene, are used [see [[Carvedilol overdosage|Overdosage ]]].
| |
| | |
| | |
| ==Drug-Drug Interactions==
| |
| Since carvedilol undergoes substantial oxidative metabolism, the metabolism and pharmacokinetics of carvedilol may be affected by induction or inhibition of [[cytochrome P450]] enzymes.
| |
| | |
| ====Amiodarone====
| |
| In a pharmacokinetic trial conducted in 106 Japanese subjects with heart failure, coadministration of small loading and maintenance doses of [[amiodarone]] with carvedilol resulted in at least a 2-fold increase in the steady-state trough concentrations of S(-)-carvedilol[see Drug Interactions (7.6)].
| |
| | |
| ====Cimetidine====
| |
| In a pharmacokinetic trial conducted in 10 healthy male subjects, [[cimetidine ]](1,000 mg/day) increased the steady-state AUC of carvedilol by 30% with no change in Cmax [see Drug Interactions (7.5)].
| |
| | |
| ====Digoxin====
| |
| Following concomitant administration of carvedilol (25 mg once daily) and [[digoxin]] (0.25 mg once daily) for 14 days, steady-state AUC and trough concentrations of digoxin were increased by 14% and 16%, respectively, in 12 hypertensive subjects [see Drug Interactions (7.4)].
| |
| | |
| ====Glyburide====
| |
| In 12 healthy subjects, combined administration of carvedilol (25 mg once daily) and a single dose of [[glyburide]] did not result in a clinically relevant pharmacokinetic interaction for either compound.
| |
| | |
| ====Hydrochlorothiazide====
| |
| A single oral dose of carvedilol 25 mg did not alter the pharmacokinetics of a single oral dose of [[hydrochlorothiazide]] 25 mg in 12 subjects with hypertension. Likewise, hydrochlorothiazide had no effect on the pharmacokinetics of carvedilol.
| |
| | |
| ====Rifampin====
| |
| In a pharmacokinetic trial conducted in 8 healthy male subjects, [[rifampin]] (600 mg daily for 12 days) decreased the AUC and Cmax of carvedilol by about 70% [see Drug Interactions (7.5)].
| |
| | |
| ====Torsemide====
| |
| In a trial of 12 healthy subjects, combined oral administration of carvedilol 25 mg once daily and [[torsemide]] 5 mg once daily for 5 days did not result in any significant differences in their pharmacokinetics compared with administration of the drugs alone.
| |
| | |
| ====Warfarin====
| |
| Carvedilol (12.5 mg twice daily) did not have an effect on the steady-state [[prothrombin time]] ratios and did not alter the pharmacokinetics of R(+)- and S(-)-[[warfarin]] following concomitant administration with warfarin in 9 healthy volunteers.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = COREG (CARVEDILOL) TABLET, FILM COATED [GLAXOSMITHKLINE LLC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c57982f2-c7da-488a-7ea9-b9609439ac68#nlm34089-3 | publisher = | date = | accessdate = }}</ref>
| |
| | |
| ==References==
| |
| {{Reflist}}
| |
| | |
| {{FDA}}
| |
|
| |
|
| | [[Category:Beta Blockers]] |
| [[Category:Cardiovascular Drugs]] | | [[Category:Cardiovascular Drugs]] |
| [[Category:Drugs]] | | [[Category:Drugs]] |